Ziagen(abacavir)
Epzicom, Kivexa, Triumeq, Trizivir, Ziagen (abacavir) is a small molecule pharmaceutical. Abacavir was first approved as Ziagen on 1998-12-17. It is used to treat acquired immunodeficiency syndrome and HIV infections in the USA. It has been approved in Europe to treat HIV infections.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| urogenital diseases | D000091642 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Ziagen (generic drugs available since 2012-06-18)
CombinationsEpzicom, Triumeq, Trizivir (generic drugs available since 2012-06-18)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Abacavir sulfate
Abacavir sulfate
+
Dolutegravir sodium
+
Lamivudine
Abacavir sulfate
+
Lamivudine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| EPZICOM | ViiV Healthcare | N-021652 RX | 2004-08-02 | 1 products, RLD, RS |
Abacavir sulfate
+
Lamivudine
+
Zidovudine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TRIZIVIR | ViiV Healthcare | N-021205 RX | 2000-11-14 | 1 products, RLD, RS |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| acquired immunodeficiency syndrome | EFO_0000765 | D000163 | B20 |
| hiv infections | EFO_0000764 | D015658 | B20 |
Agency Specific
FDA
EMA
No data
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AF: Nucleoside and nucleotide reverse transcriptase inhibitors
— J05AF06: Abacavir
— J05AR: Antivirals for treatment of hiv infections, combinations
— J05AR02: Lamivudine and abacavir
— J05AR04: Zidovudine, lamivudine and abacavir
— J05AR13: Lamivudine, abacavir and dolutegravir
HCPCS
No data
Clinical
Clinical Trials
165 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 15 | 28 | 36 | 27 | 18 | 123 |
| Hiv | D006678 | O98.7 | 3 | 2 | 4 | 9 | 1 | 18 | |
| Infections | D007239 | EFO_0000544 | 3 | 1 | 6 | 3 | 2 | 15 | |
| Lipodystrophy | D008060 | E88.1 | — | 2 | — | 1 | 1 | 4 | |
| Hiv-1 | D015497 | — | 1 | 1 | 1 | — | 3 | ||
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | — | 1 | 2 | — | 3 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | 2 | — | 2 |
| Hiv-2 | D015498 | — | — | — | 1 | — | 1 | ||
| Hiv-associated lipodystrophy syndrome | D039682 | EFO_1001348 | — | — | — | 1 | — | 1 | |
| Patient compliance | D010349 | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | — | 1 | 1 | — | — | 2 |
| Lactic acidosis | D000140 | EFO_1000036 | E87.20 | — | 1 | 1 | — | — | 1 |
| Aids dementia complex | D015526 | EFO_0002608 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 2 | — | — | — | — | 2 | ||
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | — | — | — | — | 1 |
| Hepatitis c | D006526 | B19.2 | 1 | — | — | — | — | 1 | |
| Psoriasis | D011565 | EFO_0000676 | L40 | 1 | — | — | — | — | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ABACAVIR |
| INN | abacavir |
| Description | Abacavir is a 2,6-diaminopurine that is (1S)-cyclopent-2-en-1-ylmethanol in which the pro-R hydrogen at the 4-position is substituted by a 2-amino-6-(cyclopropylamino)-9H-purin-9-yl group. A nucleoside analogue reverse transcriptase inhibitor (NRTI) with antiretroviral activity against HIV, it is used (particularly as the sulfate) with other antiretrovirals in combination therapy of HIV infection. It has a role as a HIV-1 reverse transcriptase inhibitor, an antiviral drug and a drug allergen. |
| Classification | Small molecule |
| Drug class | antivirals: carbocyclic nucleosides |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1 |
Identifiers
| PDB | — |
| CAS-ID | 136470-78-5 |
| RxCUI | 190521 |
| ChEMBL ID | CHEMBL1380 |
| ChEBI ID | 421707 |
| PubChem CID | 441300 |
| DrugBank | DB01048 |
| UNII ID | WR2TIP26VS (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 10,058 documents
View more details
Safety
Black-box Warning
Black-box warning for: Epzicom, Triumeq, Trizivir, Ziagen
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more